Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

GÜMÜŞ, MAHMUTBondarenko, I.Sezer, A.Kilickap, S.ÖZGÜROĞLU, MustafaGogishvili, M.Turk, H. M.Cicin, I.Bentsion, D.Gladkov, O.Clingan, P.Sriuranpong, V.Rizvi, N.Mcginniss, J.Pouliot, J.Lee, S.Seebach, F.Lowy, I.Gullo, G.Rietschel, P.2021-11-232021-11-232021-10-01Bondarenko I., Sezer A., Kilickap S., GÜMÜŞ M., ÖZGÜROĞLU M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1-, JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.10, 2021http://hdl.handle.net/20.500.12645/29649Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1ArticleWOS:000709606500217